• Saved

September 28, 2022
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial - The Journal of Headache and Pain

Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial - The Journal of Headache and Pain

Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01480-2

Background In Italy, monoclonal antibodies targeting the CGRP pathway are subsidized for the preventive treatment of high frequency and chronic migraine (CM) in patients with a MIgraine Disability ASsessment (MIDAS) score ≥ 11. Eligibility to treatment continuation requires a ≥ 50% MIDAS score reduction at three months (T3).


Conclusion: MIDASRes only partly reflects the 12-month outcome of erenumab treatment in CM, as it excludes more than one third of responders. A criterion based on the alternative consideration of ≥ 50% reduction in MIDAS score or MMDs in the first three months of treatment represents a more precise and inclusive option.